Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$0.91
-$0.03(-0.72%)
At close: 4:00 PM EST
$0.91
-$0.03(-0.72%)
Day’s Range― - ―
52-Week Range$0.55 - $2.22
Previous CloseN/A
Volume2.88K
Average Volume (3M)55.77K
Market Cap
$10.80M
Enterprise Value-$8.70M
Total Cash (Recent Filing)$14.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.99
Next Earnings
May 18, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding11,452,452
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.42
Price to Sales (P/S)19.52
P/FCF Ratio-0.43
Enterprise Value/Market Cap-0.81
Enterprise Value/Revenue-30.46
Enterprise Value/Gross Profit-32.97
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$4.40Price Target Upside383.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.83
Revenue Forecast (FY)$150.00K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEarly single-agent tumor responses for APR-1051 in biomarker-defined endometrial cancer indicate initial proof-of-concept that could support faster clinical advancement and stronger investor confidence.
Institutional SupportParticipation by key healthcare investors in an equity financing after a confirmed response signals institutional confidence that can enhance funding flexibility and reduce perceived development risk.
Safety And DosingA cleaner toxicity profile and continuous dosing strategy for APR-1051 relative to other WEE1 inhibitors suggests a wider therapeutic window that may enable combination regimens and improved tolerability.
Bears Say
Class Toxicity And Dose RiskToxicity challenges common to WEE1 inhibitors and the potential for dose-limiting adverse events or pharmacokinetic saturation could constrain dose escalation and limit clinical upside.
Financing And DilutionA planned equity financing to sustain clinical development could produce significant shareholder dilution that materially depresses per-share valuation despite extending runway.
Limited Clinical EvidenceClinical data are limited to a small number of patients with some responses unconfirmed, meaning additional patients and confirmatory scans are required to validate efficacy signals.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $2.22 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $10.80M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is May 18, 2026 which is in 30 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Mar 16, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $0.07.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.2.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 11,452,452 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went up 2.717%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$4.40
▲(383.52% Upside)
Technical Analysis
Ownership Overview
6.81% Insiders
0.51% Mutual Funds
11.41% Other Institutional Investors
81.09% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---